<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 1, 2019 (HealthDay News) — Marine omega-3 supplementation seems to lower the risk for myocardial infarction, coronary heart disease (CHD) mortality, total CHD events, cardiovascular disease (CVD) mortality, and total CVD events, according to a review published online Sept. 30 in the Journal of the American Heart Association<\/i>.<\/p>\n
Yang Hu, Sc.D., from Harvard T.H. Chan School of Public Health in Boston, and colleagues conducted an updated meta-analysis using study-level data from 13 randomized, controlled trials, including three recent large trials, to examine the correlation between marine omega-3 supplementation and the risk for CVD. The dose-response relationship between marine omega-3 dosage and risk for myocardial infarction, CHD death, total CHD, total stroke, CVD death, total CVD, and major vascular events was examined.<\/p>\n
The researchers found that marine omega-3 supplementation correlated with a significantly lower risk for myocardial infarction, CHD mortality, total CHD events, CVD mortality, and total CVD events in the analysis excluding the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT; rate ratios, 0.92, 0.92, 0.95, 0.93, and 0.97, respectively). For all outcomes, inverse associations were strengthened after including REDUCE-IT, although statistically significant heterogeneity was introduced. For total CVD and major vascular events, statistically significant linear dose-response relationships were found in the analyses with and without including REDUCE-IT.<\/p>\n
“Additional large trials testing high doses of marine omega-3 supplementation are warranted to confirm and extend these findings,” the authors write.<\/p>\n
One author disclosed financial ties to the nutrition industry.<\/p>\n